Regulatory ProfessionalsRegulatory ProfessionalsRegulatory ProfessionalsRegulatory Professionals
  • About Us
    • Our Story
    • Leadership
    • Senior Consultants
  • Services
    • Overview
    • Regulatory Affairs Strategy
    • Electronic Publishing | eCTD Services
    • Medical and Regulatory Writing
    • Quality Assurance
    • Project Management
    • Electronic Trial Master Files (eTMFs)
  • Resources
    • Blog
    • White Papers
    • News
  • Careers
  • Contact

Regulatory CMC for Biologics / Biopharmaceuticals

    Home CMC Regulatory CMC for Biologics / Biopharmaceuticals
    NextPrevious

    Regulatory CMC for Biologics / Biopharmaceuticals

    By Regulatory Professionals | CMC, White Papers | Comments are Closed | 1 October, 2019 | 0

    Learn about Master Cell Bank concerns and other areas of concern. Download the white paper here.

    No tags.
    Avatar

    Regulatory Professionals

    More posts by Regulatory Professionals

    Related Post

    • RPI Acquired by Premier Research to Expand Regulatory Offerings

      By Regulatory Professionals | Comments are Closed

      NEWARK, Calif., JULY 30, 2018 — Regulatory Professionals, Inc., has joined Premier Research, a global provider of clinical development services, in a partnership that will offer regulatory solutions to biotechnology, pharmaceutical, and medical device companies.Read more

    • Streamline Early Clinical Development With an INTERACT Meeting

      By Ann Leonard | Comments are Closed

      In October 2018, the Food and Drug Administration (FDA) issued Standard Operating Policy and Procedure (SOPP) – SOPP 8214 Version 1.0: INTERACT Meetings with Sponsors for Drugs and Biological Products.Read more

    • FDA Releases Draft Guidance for Transdermal Product Development

      By Lisa Crose | Comments are Closed

      Transdermal and topical delivery systems (TDS) are important dosage forms that allow delivery of a drug to local tissue or provide systemic delivery through the skin. These drug products provide a number of advantages forRead more

    • UPDATE – Draft FDA Guidance Concerning Combination Products

      By Ann Leonard | Comments are Closed

      As those working in the development of combination products likely know, the Food and Drug Administration (FDA) issued two new draft guidances in December 2019.Read more

    • FDA Issues Guidance on Clinical Trials During COVID-19

      By Nach Davé | Comments are Closed

      Earlier this week, the FDA issued a guidance on the conduct of clinical trials during the ongoing Coronavirus Disease 2019 (COVID-19) pandemic.Read more

    • Global Health Authorities Push for Rapid Development of COVID-19 Tests, Drugs and Vaccines

      By Katharine Chorlton | Comments are Closed

      In response to the Coronavirus Disease 19 (COVID-19) pandemic, the scientific community, industry, and regulatory agencies are pulling together to facilitate the development of diagnostic tests, drugs, and vaccines to help prevent the spread ofRead more

    • What Is FDA’s Emergency Use Authorization (EUA) and How Can It Help Develop Therapies Faster?

      By Nach Davé | Comments are Closed

      As we continue to face health emergencies and imminent threats to our safety and well-being, the medical community is tasked with bringing solutions to the patients in an expedited and safe manner.Read more

    • Businesswoman using laptop in office

      Why Did My NDA Become a BLA on March 23, 2020?

      By Nach Davé | Comments are Closed

      During these challenging times when the world is focused on COVID-19 and the matters at hand, it’s understandable if you didn’t take much notice of March 23 as a significant date – one that’s beenRead more

    NextPrevious

    Recent Posts

    • Speed vs Safety: How Regulators Are Sizing Up Evidence Today
    • Beware of Underestimating the Value of a Pre-NDA Meeting
    • Outsourcing-Pharma.com: Holistic Approach Benefits Drug Development
    • 5 Tips to Avoid an IND Clinical Hold: Regulatory Guidance and Insights
    • The FDA Is Ending Its Rare Pediatric Disease Priority Review Vouchers – and Time Is Running Out to Get One

    Categories

    • Blog
    • CMC
    • COVID-19
    • FDA
    • INTERACT Meeting
    • News
    • Podcast
    • Regulatory Affairs
    • Uncategorized
    • White Papers
    March 2021
    M T W T F S S
    « Feb    
    1234567
    891011121314
    15161718192021
    22232425262728
    293031  

    Headquarters

    8000 Jarvis Ave.
    Suite 100
    Newark, CA 94560

    North Carolina

    One Park Drive, Suite 150
    Box 13608
    Research Triangle Park,
    NC 27709

    San Diego

    Aventine Building
    8910 University Center Lane
    Suite 400 San Diego, CA 92122

    United Kingdom

    250 South Oak Way
    Green Park
    Reading, Berkshire, RG2 6UG

    Australia

    Premier Research Australia Pty Ltd.
    Ground Floor, 23 Milton Parade
    Malvern VIC 3144

    • Home
    • About Us
    • Services
    • Cookie Policy
    • Privacy Notice
    • Contact
    Copyright 2021 Regulatory Professionals | All Rights Reserved
    • About Us
      • Our Story
      • Leadership
      • Senior Consultants
    • Services
      • Overview
      • Regulatory Affairs Strategy
      • Electronic Publishing | eCTD Services
      • Medical and Regulatory Writing
      • Quality Assurance
      • Project Management
      • Electronic Trial Master Files (eTMFs)
    • Resources
      • Blog
      • White Papers
      • News
    • Careers
    • Contact
    Regulatory Professionals
    XWe use cookies (and equivalent technologies) to collect and analyze information on our Website’s performance and to enable the Website to function. Cookies also allow us and third parties to tailor the ads you see when you visit our Website and other third party websites in the same online network, including social networks. By clicking ‘AGREE', you agree to these uses of cookies. If you do not agree or if you would like more information, you can manage your cookie preferences by clicking on 'Cookie Settings'. Cookie Policy REJECTAGREECookie Settings
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled

    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

    Non Necessary

    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

    Save & Accept